HuGE Literature Finder
|
||
Records 1-7
|
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Gynecologic oncology 2019 May . Tomao Federica, Musacchio Lucia, Di Mauro Federica, Boccia Serena Maria, Di Donato Violante, Giancotti Antonella, Perniola Giorgia, Palaia Innocenza, Muzii Ludovico, Benedetti Panici Pierlui |
|
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Cancer 2018 Apr 124 (7): 1374-1382. O'Reilly Eileen M, Lee Jonathan W, Lowery Maeve A, Capanu Marinela, Stadler Zsofia K, Moore Malcolm J, Dhani Neesha, Kindler Hedy L, Estrella Hayley, Maynard Hannah, Golan Talia, Segal Amiel, Salo-Mullen Erin E, Yu Kenneth H, Epstein Andrew S, Segal Michal, Brenner Robin, Do Richard K, Chen Alice P, Tang Laura H, Kelsen David |
|
BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2017 Nov . Kotsopoulos Joanne, Willows Karla, Trat Sandra, Kim Raymond H, Volenik Alexandra, Sun Ping, Narod Steven A, Boyd Jeffrey, May Taym |
|
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Oncotarget 2017 Oct 8 (45): 79175-79187. Lee Jung-Min, Hays John L, Chiou Victoria L, Annunziata Christina M, Swisher Elizabeth M, Harrell Maria I, Yu Minshu, Gordon Nicolas, Sissung Tristan M, Ji Jiuping, Figg William D, Minasian Lori, Lipkowitz Stanley, Wood Bradford J, Doroshow James, Kohn Elise |
|
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
|
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
|
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
The New England journal of medicine 2009 Jul 361 (2): 123-34. Fong Peter C, Boss David S, Yap Timothy A, Tutt Andrew, Wu Peijun, Mergui-Roelvink Marja, Mortimer Peter, Swaisland Helen, Lau Alan, O'Connor Mark J, Ashworth Alan, Carmichael James, Kaye Stan B, Schellens Jan H M, de Bono Johann |
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 22, 2019
- Content source: